Shuttle Pharmaceuticals Holdings, Inc. — Form 8-K/A
Filed August 17, 2026 · analyzed by the 8-K Agent
8-K/A
— Neutral
significance 45/100
What the filing says
This is an amended 8-K (Form 8-K/A) filed by Shuttle Pharmaceuticals Holdings, Inc. on August 17, 2026, reporting completion of an acquisition or disposition of assets (Item 2.01). The original report period was May 1, 2026. The filing contains XBRL financial statement exhibits but the specific acquisition details—counterparty name, transaction value, deal terms, and asset description—are not disclosed in the document metadata or header text provided.
Why this rating
Acquisition completion is ordinarily material; however, absence of transaction specifics (price, counterparty, assets) prevents full assessment. At $4.7M market cap, even small deals could be meaningful, but lack of disclosed dollar amount limits scoring. Routine amended filing mechanics.
Extracted items
- 2.01 acquisition/disposition
- 9.01 exhibits
See more from August 17, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.